Ruti Aga: the forged prescription that turned a two-year sanction into six
**मुख्य उत्तर:** इथियोपियाई मैराथन धावक रुति अगा पर छह साल का प्रतिबंध लगा है — दो साल मिथाइलप्रेडनिसोलोन की मौजूदगी के लिए और चार साल जाँच के दौरान नकली मेडिकल पर्चा पेश करने यानी टैंपरिंग के लिए। प्रतिबंध की गिनती 10 सितंबर से है, जो उनके अनंतिम निलंबन की तारीख है। **मुख्य तथ्य:** - रुति अगा (इथियोपिया, 32 वर्ष) पर छह साल का प्रतिबंध; दो साल मौजूदगी और चार साल टैंपरिंग के लिए। - मार्च में चीन में जीती गई हाफ मैराथन के बाद लिया गया नमूना पॉज़िटिव निकला; 10 सितंबर से अनंतिम निलंबन जारी था। - मिथाइलप्रेडनिसोलोन WADA सूची का S9 ग्लूकोकॉर्टिकोइड है, एनाबॉलिक स्टेरॉयड नहीं; केवल प्रतियोगिता के दौरान प्रतिबंधित। - पर्चा ऐसे क्लिनिक के नाम पर था जिसका अस्तित्व नहीं था; जारी करने वाला परिवार का सदस्य, कोई मेडिकल पंजीकरण नहीं। - 2019 टोक्यो मैराथन खिताब और वर्ल्ड मैराथन मेजर्स में तीन दूसरे स्थान उनके रिकॉर्ड में दर्ज हैं। **स्रोत:** एथलेटिक्स इंटीग्रिटी यूनिट (AIU) का आधिकारिक बयान, गुरुवार को जारी; बयान की सटीक प्रकाशन तिथि और मार्च वाली रेस का वर्ष मूल रिपोर्ट में नहीं दिया गया है। **संबंधित प्रश्न-उत्तर:** प्रश्न: रुति अगा पर छह साल का प्रतिबंध क्यों लगा? उत्तर: दो साल दवा की मौजूदगी के लिए और चार साल नकली पर्चे के ज़रिए जाँच को भ्रमित करने के लिए, कुल छह साल। प्रश्न: मिथाइलप्रेडनिसोलोन किस श्रेणी की दवा है? उत्तर: यह WADA प्रतिबंधित सूची का S9 ग्लूकोकॉर्टिकोइड है और केवल प्रतियोगिता के दौरान प्रतिबंधित है, एनाबॉलिक स्टेरॉयड नहीं। प्रश्न: क्या 2019 टोक्यो मैराथन खिताब रद्द हुआ है? उत्तर: AIU बयान में रद्दीकरण का दायरा नहीं बताया गया; मानक प्रक्रिया के अनुसार मार्च वाली रेस का नतीजा और पुरस्कार राशि रद्द मानी जाती है, जबकि उससे पहले के नतीजे स्वतः रद्द नहीं होते।
A prescription exists. It carries a clinic's letterhead, a doctor's signature, a date, and a note about an injection into a knee. The difficulty is that the clinic never existed. The sharpest line in the Athletics Integrity Unit's statement on Thursday is not about methylprednisolone; it is about that piece of paper. And that line rewrites the arithmetic of Ethiopian marathoner Ruti Aga's career.
The sum is simple. Two years for the presence of a substance. Four years for tampering, for producing a misleading document during the investigation. Six years in total, counted from 10 September, the date her provisional suspension began. No photo finish, no weather reading, no split. One date, one document, six years.

The record book still credits her with the 2026 Tokyo Marathon title and three runner-up finishes at World Marathon Majors. She is 32, a 2:18-to-2:20 class marathoner, which in Ethiopia means not a guaranteed championship pick but a name on a selection queue. The statement gives no personal best, no time for the March race, no field strength. The figure I have in my own notes — roughly 2:18:34 for second place in Berlin in 2026 — comes from my file, not from the AIU.
What the statement does establish is this: a half marathon in China in March, which she won, and a positive sample afterwards. A road race's testing window opens at 23:59 the night before the race, which means an injection given days earlier can still be caught if residue remains. The statement does not spell out the year of the March race or the calendar year in which the ban expires.

Here is where nearly every report has slipped. Methylprednisolone is being described as an anabolic steroid. It is not. It is a glucocorticoid, class S9 on the WADA Prohibited List, and S9 substances are prohibited in-competition only — by injection, orally or rectally. That distinction is not technical housekeeping; it is the spine of the case. If the substance is banned only in-competition, everything turns on route and timing, not on the accumulation of a banned agent.
A therapeutic knee injection is entirely lawful out of competition. It becomes a violation only when residue is present on race day. The mislabelling matters because it pushes readers to compare this file with anabolic-steroid cases, where the comparison does not hold. It also explains why a defence was available.
The knee-injury explanation is not medically absurd. Intra-articular or peri-articular methylprednisolone for knee synovitis is standard practice in distance runners. The problem is that genuine treatment would have been defended with genuine records: a clinic register, a registration number, the injection date, its distance from the race. On the day a document had to be manufactured, the admission was that no real document existed.
According to the statement, the prescription carried the name of a clinic with no existence. The person who issued it was a family member with no medical registration, who claimed to have used an old prescription pad from a former workplace. The clinic disowned the pad. Three independent verifications, three failures. I struggle to recall another athletics file with a three-stage verification collapse of that kind.
The four-year tampering sanction did not come from the document alone. It came from an interview — from statements made under questioning. That detail matters, because it means the athlete did not merely hand over a paper; she narrated it.
And the question nobody is asking: what if the prescription had been real? A TUE, or observance of the route-specific washout period, or an honest medical file — any one of those would have allowed the presence charge to be argued at the no-fault end, possibly down to a reprimand, with no tampering charge at all. In the best case there would have been no case. Four of those six years were bought not by a substance but by a document.
In 2026, while the Dutee Chand CAS hearing ran, I was on an agency desk filing results. The argument there was physiology and regulation — the definition of hyperandrogenism, burden of evidence, expert testimony. Here the argument stopped at a document that could have been checked in an afternoon. Both ended against the athlete, but for different reasons: in one, the rule fought; in the other, the paper lost.
The root of this affair is not the knee. It is the vacuum around the knee — a setup with no credentialed team physician in it. Since I left the wire desk in 2026 for my first women's league commentary booth, I have held one rule: I do not enter a booth without a prepared sheet, and every physical-profile line is written from my own notes, not a press release. An athlete should have had the equivalent sheet. She did not.
This is larger than individual carelessness. A marathoner's income leans heavily on appearance fees, and appearance fees depend on showing up. Injury creates pressure to mask pain, and the cheapest, most available tool for masking pain is a glucocorticoid injection. Where credentialed medical support is absent, that tool arrives through informal networks. The forged prescription is a product of that gap, not its cause.
Where it happened is a signal in itself. China's label-race circuit is the income tier between Majors for East African marathoners — good money, apparently low paperwork risk. It is also now the AIU's highest-yield testing ground. The appearance-fee economy and the testing economy are colliding inside the same races, and that collision will continue.
One correction is necessary, because the temptation to invert is strong. Reading this as an anti-doping triumph is wrong, and reading it as proof of disproportionate enforcement against African runners is also wrong. Nobody runs 2:18 on a glucocorticoid; it builds no muscle, raises no blood count, supplies no endurance engine. The six years were not bought by performance gain but by paperwork. Equally, the panel did not misread the file. The presence violation is straightforward: the substance was in the sample, in competition, with no valid medical basis offered. This is not a place to invert, because the document does not license it.
What the document does license is a reading of the sanction's architecture. Two years for presence plus four for tampering matches the Code's standard structure, and it tells us the panel found no aggravating intent behind the presence charge — hence two years — while treating the forged document as fully culpable. Backdating to 10 September is procedural, not lenient: provisional suspension time counts against the ban, so the athlete gains nothing in real terms.
Career arithmetic is harsher. A six-year ban removes the 2028 Olympic cycle entirely; at 32, a return would arrive around 38. Here a caution is needed: what makes her unselectable is not the sanction but Ethiopian depth. In a country where a 2:18 performer is not automatically picked, a 38-year-old with a doping record has a mathematically zero selection pathway. That is demography, not severity.
An appeal is available, typically within about 21 days of the reasoned decision to CAS. Overturning a document-based finding is difficult, because the argument there is verification, not interpretation. One question the statement leaves open: whether the forgery attracts any national-level action. The AIU's jurisdiction ends there, and the silence afterwards speaks as plainly as the clinic's denial.

Those who file this away as a clean enforcement win will miss the shift: the enforcement frontier has moved from detection to document verification. The informal medical network that produced one prescription serves many athletes in the same training cluster. The next instalment will come from the same group. The open question is whether an entourage is ever charged — the statement names only a family member, with no mention of any inquiry into an agent or management.
The record book will keep Tokyo 2026. In the margin there will be a date. And that date came not from a substance but from a prescription whose clinic never existed.
